Augmentative effects of phytohemagglutinin-P on proliferation and cytotoxicity of interleukin-2-activated canine peripheral blood lymphocytes

Journal of Veterinary Medicine Series A: Physiology Pathology Clinical Medicine

Volumn 43, Issue 5, 1996, Pages 289-296

  Mizuno, S ^a,b   Fujinaga, T ^b   Kurosawa, T ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; MITOGENIC AGENT; PHYTOHEMAGGLUTININ; PHYTOHEMAGGLUTININ P; PHYTOHEMAGGLUTININ-P; RECOMBINANT PROTEIN;

ANIMAL; ARTICLE; CELL CULTURE; CYTOLOGY; DOG; DRUG EFFECT; FEMALE; HUMAN; LYMPHOCYTE ACTIVATION; LYMPHOKINE ACTIVATED KILLER CELL; MALE; PHYSIOLOGY;

ANIMALS; CELLS, CULTURED; DOGS; FEMALE; HUMANS; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; LYMPHOCYTE ACTIVATION; MALE; MITOGENS; PHYTOHEMAGGLUTININS; RECOMBINANT PROTEINS;

EID: 2842557344     PISSN: 0931184X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1439-0442.1996.tb00455.x     Document Type: Article

References (26)

1. DAMLE, N. K., L. V. DOYLE, and E. C. BRADLEY, 1986: Interleukin-2-activated human killer cells are derived from phenotypically heterogeneous precursors. J. Immunol. 137, 2814-2822.
2. DEBATIN, K., C. WOODROOFE, H. LAHM, J. FISCHER, W. FALK, W. E. BRANDEIS, and P. H. KRAMMER, 1989: Lack of interleukin-2 (IL-2) dependent growth of TAC positive T-ALL/ NHL cells is due to the expression of only low affinity receptors for IL-2. Leukemia 3, 566-571.
3. FUJINAGA, T., M. YAMASHITA, M. C. YOSHIDA, S. MIZUNO, Y. OKAMOTO, M. TAJIMA, and K. OTOMO, 1989: Choromosome analysis of canine transmissible sarcoma cells. J. Vet. Med. A 36, 481-489.
4. GRIMM, E. A., A. MAZUMDER, H. Z. ZHANG, and S. A. ROSENBERG, 1982: Lymphokine-activated killer cell phenomenon: Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155, 1823-1841.
5. HELFAND, S. C., J. F. MODIANO, and P. C. NOVELL, 1992: Immunophysiological studies of interleukin-2 and canine lymphocytes. Vet. Immunol. Immunopathol. 33, 1-16.
6. HSU, S., L. RAINE, and H. FANGER, 1981: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedure. J. Histochem. Cytochem. 29, 577-580.
7. ITOH, K., K. SHIIBA, Y. SHIMIZU, R. SUZUKI, and K. KUMAGAI, 1985: Generation of activated killer (AK) cells by recombinant interleukin-2 (rhIL-2) in collaboration with interferon-γ (INF-γ). J. Immunol. 134, 3124-3129.
8. JARDINE, J. H., H. J. JACKSON, E. LOTZOVA, C. A. SAVARY, and S. M. SMALL, 1989: Tumoricidal effect of interleukin-2-activated killer cells in canines. Vet. Immunol. Immunopathol. 21, 153-160.
9. KALLAND, T., H. BELFRAGE, P. BHILADVALA, and G. HEDLUND, 1987: Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: Dissection of effectors and progenitors into NK- and T-like cells. J. Immunol. 138, 3640-3645.
10. KIMOTO, Y., T. TANAKA, A. FUJIWARA, M. FUJITA, and T. TAGUCHI, 1992: Enhancing effect of pokeweed mitogen on the proliferation and the cytotoxicity of lymphokine-activated killer cells. Jpn. J. Cancer Res. 83, 631-637.
11. KULL, F. C., and P. CUATRECASAS, 1981: Possible requirement of internalization in the mechanism of in vitro cytotoxicity in tumor necrosis serum. Cancer Res. 41, 4885-4890.
12. LOUGHRAN, T. P., H. J. DEEG, and R. STOBB, 1985: Morphologic and phenotypic analysis of canine natural killer cells: Evidence for T-cell lineage. Cell. Immunol. 95, 207-217.
13. MAAS, R. A., H. F. J. DULLENS, and W. D. OTTER, 1993: Interleukin-2 in cancer treatment: Disappointing or (still) promising? A review. Cancer Immunol. Immunother. 36, 141-148.
14. MITCHELL, D. H., S. J. WITHROW, M R. JOHNSTON, and C. A. KRUSE, 1991: Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors. Am. J. Vet. Res. 52, 1132-1136.
15. MIZUNO, S., T. FUJINAGA, M. TAJIMA, K. OTOMO, and T. KOIKE, 1989: Role of lymphocytes in dogs experimentally re-challenged with canine transmissible sarcoma. Jpn. J. Vet. Sci. 51, 86-95.
16. MOORE, A. S., G. H. THEILEN, A. D. NEWELL, B. R. MADEWELL, and A. R. RUDOLF, 1991: Preclinical study of sequential tumor necrosis factor and interleukin-2 in the treatment of spontaneous canine neoplasms. Cancer Res. 51, 233-238.
17. OCHOA, A. C., D. E. HASZ, R. REZONZEW, P. M. ANDERSON, and F. H. BACH, 1989: Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin-2: Identification and isolation of effector subsets. Cancer Res. 49, 963-968.
18. RAMSDELL, F. J., H. SHAU, and S. H. GOLUB, 1988: Role of proliferation in LAK cell development. Cancer Immunol. Immunother. 26, 139-144.
19. RASKIN, R. E., C. S. HOLCOMB, and A. K. MAXWELL, 1991: Effects of human recombinant interleukin-2 on in vitro tumor cytotoxicity in dogs. Am. J. Vet. Res. 52, 2029-2032.
20. SOMBERG, R. L., J. P. ROBINSON, and P. J. FELSBURG, 1992: Detection of canine interleukin-2 receptors by flow cytometry. Vet. Immunol. Immunopathol. 33, 17-24.
21. TANIGUCHI, T., and Y. MINAMI, 1993: The IL-2/IL-2 receptor system: A current overview. Cell 73, 5-8.
22. TESTA, U., A. CARE, E. MONTESORO, C. FOSSATI, G. GIANNELLA, R. MASCIULLI, M. FAGIOLI, D. BULGARINI, D. HABETSWALLNER, G. ISACCHI, P. G. PELICCI, and C. PESCHLE, 1990: Interleukin-2-dependent long-term cultures of low-density lymphocytes allow the proliferation of lymphokine-activated killer cells with natural killer, Tiγ/δ or TNK phenotype. Cancer Immunol. Immunother. 31, 11-18.
23. WEIL-HILLMAN, G., S. D. VOSS, P. FISCH, K. SCHELL, J. A. HANK, J. A. SOSMAN, K. SUGAMURA, and P. M. SONDEL, 1990: Natural killer cells activated by interleukin-2 treatment in vivo respond to interleukin-2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype. Cancer Res. 50, 2683-2691.
24. WERSALL, P., G. MASUCCI, P. PIHLSTEDT, H. WIGZELL, and H. MELLSTEDT, 1990: Symplified long-term large scale production of highly active human LAK cells for therapy. Med. Oncol. Tumor Pharmacother. 7, 257-263.
25. WHITTINGTON, R., and D. FAULDS, 1993: Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 46, 446-514.
26. YOKOTA, S., T. SHIRASAKA, H. NISHIKAWA, S. HOSOE, T. IKEDA, K. KOMUTA, I. KAWASE, T. MASUNO, T. OGURA, and S. KISHIMOTO, 1988: Augmentative effect of Nocardia rubra cell-wall skeleton (N-CWS) on lymphokine-activated killer (LAK) cell induction. Cancer Immunol. Immunother. 26, 11-17.